Incyte (INCY) Change in Receivables (2010 - 2026)
Incyte's (INCY) quarterly Change in Receivables came in at $73.8 million in Q2 2026, up 264.8% on a YoY basis from $20.2 million in Q2 2025, and up 173.04% quarter-over-quarter from $27.0 million in Q1 2026.
Analysis
Incyte (INCY) Change in Receivables (2010 - 2026) Analysis & Trends
Incyte (INCY) has reported Change in Receivables for 17 consecutive years, with $73.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Receivables rose 264.8% year-over-year to $73.8 million; the trailing twelve-month figure through Jun 2026 stood at $282.3 million (up 167.94% YoY), and the FY2025 full-year result was $170.8 million, up 53.04% from the prior year.
- Change in Receivables grew to $73.8 million in Q2 2026 per INCY's latest filing, from $27.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $128.5 million in Q4 2025 and bottomed at -$64.8 million in Q3 2022.
- Historically, Change in Receivables has averaged $28.4 million across 5 years, with a median of $19.8 million in 2024.
- The widest YoY moves for Change in Receivables: up 412.37% in 2025, down 1672.12% in 2025.
- Over 5 years, Change in Receivables stood at $26.7 million in 2022, then soared by 223.31% to $86.3 million in 2023, then climbed by 12.05% to $96.7 million in 2024, then soared by 32.89% to $128.5 million in 2025, then plunged by 42.57% to $73.8 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $73.8 million, $27.0 million, and $128.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 117.58 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 73.80 Mn |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | -1.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73.80 Mn |
| Mar 31, 2026 | 27.03 Mn |
| Dec 31, 2025 | 128.50 Mn |
| Sep 30, 2025 | 53.00 Mn |
| Jun 30, 2025 | 20.23 Mn |
| Mar 31, 2025 | -30.96 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Dec 31, 2023 | 86.29 Mn |
| Sep 30, 2023 | 19.27 Mn |
| Jun 30, 2023 | 14.21 Mn |
| Mar 31, 2023 | -21.09 Mn |
| Dec 31, 2022 | 26.69 Mn |
| Sep 30, 2022 | -64.78 Mn |
| Jun 30, 2022 | 120.62 Mn |
| Mar 31, 2022 | -53.96 Mn |
| Dec 31, 2021 | 99.61 Mn |
| Sep 30, 2021 | 78.52 Mn |